Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II open-label study of PDR001 in advanced solid tumors
NL-OMON47776Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Jul 2015
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of spartalizumab in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), melanoma and 6 more (5 arms), sponsored by Novartis. Primary endpoints: Dose-limiting toxicities and Overall response rate. Started Jul 2015; status: active, not recruiting.
02
Drugs
spartalizumab
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)melanomatriple-negative breast cancer (TNBC)anaplastic thyroid cancer (ATC)
Beyond the preview
Go deeper on NL-OMON47776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47776.